Cowen & Co. Sticks to Its Hold Rating for Radius Health

In a report issued on May 11, Chris Shibutani from Cowen & Co. maintained a Hold rating on Radius Health (NASDAQ: RDUS). The company’s shares opened today at $33.45.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 13.9% and a 44.2% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

Radius Health has an analyst consensus of Moderate Buy, with a price target consensus of $50.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $49.16 and a one-year low of $24.66. Currently, Radius Health has an average volume of 777.6K.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RDUS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Radius Health, Inc. engages in the discovery and development of therapeutics for the treatment of osteoporosis, oncology, and endocrine diseases. The firm’s lead product, abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.